文献速递肿瘤 PET/CT放射性药物与辐射防护

BNT162b2 mRNA新冠疫苗接种后高代谢淋巴结病的[18F]FDG PET-CT发生率及对报告解读的影响

Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-03-27

该研究纳入728例接种BNT162b2疫苗的肿瘤患者,通过[18F]FDG PET-CT评估疫苗相关高代谢淋巴结病(VAHL)的发生率。接种后淋巴结高代谢总发生率为45.6%,其中80.1%为VAHL;加强针后VAHL更常见且摄取强度更高。建议根据VAHL低发生率的时间间隔安排PET-CT,并指导疫苗注射部位以减少肿瘤患者的假阳性或不确定报告。

要点

  • 接种BNT162b2疫苗后,肿瘤患者PET-CT中淋巴结高代谢发生率达45.6%,其中80.1%为VAHL。
  • 加强针后VAHL发生率更高(53.9%)且[18F]FDG摄取强度更高。
  • 首剂后5天内或第3周、加强针后20天以上VAHL发生率较低。

核心结论

  • BNT162b2疫苗接种后VAHL常见,加强针后更常见且摄取强度更高。
  • 为减少肿瘤患者假阳性和不确定报告,PET-CT时机应参考VAHL低发生率的时间间隔,并建议疫苗注射部位选择。

研究设计与样本

  • 单中心连续纳入951例接受[18F]FDG PET-CT检查的患者并进行疫苗接种史访谈,其中728例接种疫苗者纳入分析。
  • 接种者分为仅首剂组(346例)和首剂+加强针组(382例),PET-CT结果分为无淋巴结高代谢、恶性淋巴结高代谢、VAHL和不确定淋巴结高代谢。

主要发现

  • 全部接种组、仅首剂组和加强针组的淋巴结高代谢发生率分别为45.6%、36.4%和53.9%。
  • 接种疫苗的淋巴结高代谢患者中80.1%为VAHL。
  • 首剂后5天内或第3周、加强针后20天以上VAHL发生率较低。
  • 332例接种者中49例(14.8%)无法判定淋巴结高代谢为恶性或VAHL,乳腺癌和淋巴瘤是最常见的不确定病例疾病。

关键数值与推荐

  • VAHL定义为与疫苗接种同侧的腋窝或锁骨上淋巴结高代谢。
  • 不确定淋巴结高代谢(EqHL)指无法区分恶性与VAHL的高代谢淋巴结。

临床怎么用

  • 肿瘤患者接受[18F]FDG PET-CT时,应询问疫苗接种史和注射部位,并结合VAHL低发生率的时间间隔安排检查。
  • 对腋窝或锁骨上淋巴结为肿瘤累及相关部位的患者,建议疫苗注射部位选择对侧或避开这些区域。

局限性

  • 单中心研究,样本来自连续接受PET-CT的患者,可能存在选择偏倚。
  • VAHL和EqHL的判定基于影像和临床信息,缺乏病理确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nationwide mass vaccination against Covid-19 started in Israel in late 2020. Soon we identified on [18F]FDG PET-CT studies vaccine-associated hypermetabolic lymphadenopathy (VAHL) in axillary or supraclavicular lymph nodes (ASLN) ipsilateral to the vaccination site. Sometimes, differentiation between the malignant and benign nature of the hypermetabolic lymphadenopathy (HLN) could not be made, and equivocal HLN (EqHL) was reported. The purpose of the study was to determine the overall incidence of VAHL after BNT162b2 vaccination and also its relevance to PET-CT interpretation in oncologic patients. METHODS: A total of 951 consecutive patients that underwent [18F]FDG PET-CT studies in our department were interviewed regarding the sites and dates of the vaccine doses. A total of 728 vaccinated patients (All-Vac group) were included: 346 received the first dose only (Vac-1 group) and 382 received the booster dose as well (Vac-2 group). Studies were categorized as no HLN, malignant-HLN (MHL), VAHL, or EqHL. In studies with VAHL, location, [18F]FDG-intensity uptake and nodes size were recorded. RESULTS: The incidences of HLN were 45.6%, 36.4%, and 53.9% in All-Vac, Vac-1, and Vac-2 groups, respectively. VAHL was reported in 80.1% of vaccinated patients with HLN. Lower incidences of VAHL were found during the first 5 days or in the third week after the first vaccine and beyond 20 days after the booster dose. In 49 of 332 (14.8%) vaccinated patients, we could not determine whether HLN was MHL or VAHL. Breast cancer and lymphoma were the leading diseases with EqHL. CONCLUSION: VAHL is frequently observed after BNT162b2 administration, more commonly and with higher intensity following the booster dose. To minimize false and equivocal reports in oncological patients, timing of [18F]FDG PET-CT should be based on the time intervals found to have a lower incidence of VAHL, and choice of vaccine injection site should be advised, mainly in patients where ASLN are a relevant site of tumor involvement.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cohen D, Krauthammer SH, Wolf I, et al. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021. PMID: 33774684. doi:10.1007/s00259-021-05314-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。